Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-DRE Urine Improves Diagnosis of Prostate Cancer in Chinese Population

Table 3

Performance of PCA3 and LBXexo in predicting biopsy outcomes.

Any-grade cancer	Biopsy positive	Biopsy negative	Total	Performance
PCA3
≥Cutoff point	10	28	38	PPV %	26.32
<Cutoff point	4	15	19	NPV %	78.95
Total	14	43	57
LBXexo score
≥Cutoff point	12	17	29	PPV %	41.38
<Cutoff point	2	26	28	NPV %	92.86
Total	14	43	57
	Sensitivity %	Specificity %	% of predicted negative
PCA3	71.4	34.9	33.33
LBXexo	85.7	60.5	50.88
High-grade cancer (GS ≥ 7)	Biopsy positive	Biopsy negative + low-grade cancer	Total	Performance
PCA3
≥Cutoff point	7	31	38	PPV %	18.42
<Cutoff point	1	18	19	NPV %	94.74
Total	8	49	57
LBXexo score
≥Cutoff point	8	21	29	PPV %	27.59
<Cutoff point	0	28	28	NPV %	100
Total	8	49	57
	Sensitivity %	Specificity %	% of predicted negative
PCA3	87.5	36.7	33.33
LBXexo	100	57.1	49.12

Abbreviations: PPV, positive predictive value; NPV, negative predictive value.